HDL-cholesterol and apolipoproteins in relation to dementia

Current Opinion in Lipidology

Volumn 27, Issue 1, 2016, Pages 76-87

  Koch, Manja ^a   Jensen, Majken K ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Alzheimer's disease; apolipoproteins; dementia; HDL

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CLUSTERIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ALZHEIMER DISEASE; BLOOD FLOW; CEREBROSPINAL FLUID; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CROSS-SECTIONAL STUDY; DEMENTIA; DIAGNOSTIC TEST; EPIDEMIOLOGICAL DATA; GENOTYPE; HAZARD RATIO; HISTOPATHOLOGY; HUMAN; MEDLINE; MILD COGNITIVE IMPAIRMENT; MULTIINFARCT DEMENTIA; NERVE DEGENERATION; NON INVASIVE PROCEDURE; OBSERVATIONAL STUDY; PLASMA; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; ANIMAL; METABOLISM;

ANIMALS; APOLIPOPROTEINS; CHOLESTEROL, HDL; CROSS-SECTIONAL STUDIES; DEMENTIA; GENOTYPE; HUMANS;

EID: 84954376484     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000257     Document Type: Review

References (56)

1. Alzheimer s Disease International. World Alzheimer Report 2015. London: Alzheimer s Disease International
2. Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol. 2003; 60: 1119-1122.
3. Whiteford HA, Ferrari AJ, Degenhardt L, et al. The global burden of mental, neurological and substance use disorders: an analysis from the Global Burden of Disease Study. PLoS One. 2015; 10: e0116820.
4. Bateman R. Alzheimer s disease and other dementias: advances in 2014. Lancet Neurol. 2015; 14: 4-6.
5. Dietschy JM. Central nervous system: cholesterol turnover, brain development and neurodegeneration. Biol Chem. 2009; 390: 287-293.
6. Roheim PS, Carey M, Forte T, Vega GL. Apolipoproteins in human cerebrospinal fluid. Proc Natl Acad Sci U S A. 1979; 76: 4646-4649.
7. Demeester N, Castro G, Desrumaux C, et al. Characterization and functional studies of lipoproteins, lipid transfer proteins, and lecithin: cholesterol acyltransferase in CSF of normal individuals and patients with Alzheimer s disease. J Lipid Res. 2000; 41: 963-974.
8. Koch S, Donarski N, Goetze K, et al. Characterization of four lipoprotein classes in human cerebrospinal fluid. J Lipid Res. 2001; 42: 1143-1151.
9. Kontush A, Chapman MJ. HDL: close to our memories? Arterioscler Thromb Vasc Biol. 2008; 28: 1418-1420.
10. Holtzman DM. Role of apoe/Abeta interactions in the pathogenesis of Alzheimer s disease and cerebral amyloid angiopathy. J Mol Neurosci. 2001; 17: 147-155.
11. Zlokovic BV, Deane R, Sallstrom J, et al. Neurovascular pathways and Alzheimer amyloid beta-peptide. Brain Pathol. 2005; 15: 78-83.
12. Jiang Q, Lee CY, Mandrekar S, et al. ApoE promotes the proteolytic degradation of Abeta. Neuron. 2008; 58: 681-693.
13. Lambert JC, Heath S, Even G, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer s disease. Nat Genet. 2009; 41: 1094-1099.
14. Reitz C, Tang MX, Schupf N, et al. Association of higher levels of high-density lipoprotein cholesterol in elderly individuals and lower risk of late-onset Alzheimer disease. Arch Neurol. 2010; 67: 1491-1497.
15. Pitas RE, Boyles JK, Lee SH, et al. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B, E(LDL) receptors in the brain. J Biol Chem. 1987; 262: 14352-14360.
16. Toledo JB, Da X, Weiner MW, et al. CSF Apo-E levels associate with cognitive decline and MRI changes. Acta Neuropathol. 2014; 127: 621-632.
17. Cruchaga C, Kauwe JS, Nowotny P, et al. Cerebrospinal fluid APOE levels: an endophenotype for geneti studies for Alzheimer s disease. Hum Mol Genet 2012 21 4558-4571.
18. Ancelin ML, Ripoche E, Dupuy AM, et al. Sex differences in the associations between lipid levels and incident dementia. J Alzheimers Dis. 2013; 34: 519-528.
19. Apostolova LG, Hwang KS, Avila D, et al. Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures. Neurology. 2015; 84: 729-737. Recent study from the ADNI suggesting that apoE but not apoJ predicts progression to Alzheimer s disease in participants with MCI over 36 months follow-up.
20. Gatz M, Reynolds CA, Finkel D, et al. Dementia in Swedish twins: predicting incident cases. Behav Genet. 2010; 40: 768-775.
21. Guo LH, Alexopoulos P, Wagenpfeil S, et al. Plasma proteomics for the identification of Alzheimer disease. Alzheimer Dis Assoc Disord. 2013; 27: 337-342.
22. Johnstone D, Milward EA, Berretta R, Moscato P. Multivariate protein signatures of preclinical Alzheimer s disease in the Alzheimer s disease neuroimaging initiative (ADNI) plasma proteome dataset. PLoS One. 2012; 7: e34341.
23. Llano DA, Devanarayan V, Simon AJ. Evaluation of plasma proteomic data for Alzheimer disease state classification and for the prediction of progression from mild cognitive impairment to Alzheimer disease. Alzheimer Dis Assoc Disord. 2013; 27: 233-243.
24. Mielke MM, Bandaru VV, Haughey NJ, et al. Serum ceramides increase the risk of Alzheimer disease: the Women s Health and Aging Study II. Neurology. 2012; 79: 633-641.
25. Rasmussen KL, Tybjaerg-Hansen A, Nordestgaard BG, Frikke-Schmidt R. Plasma levels of apolipoprotein E and risk of dementia in the general population. Ann Neurol. 2015; 77: 301-311. Using data from 75 708 participants of the Copenhagen General Population Study and the Copenhagen City Heart Study, this large Danish register-based study showed HDL-C levels were significantly lower in participants progressing to dementia or Alzheimer s disease
26. Schrijvers EM, Koudstaal PJ, Hofman A, Breteler MM. Plasma clusterin and the risk of Alzheimer disease. JAMA. 2011; 305: 1322-1326.
27. IJsselstijn L, Dekker LJ, Koudstaal PJ, et al. Serum clusterin levels are not increased in presymptomatic Alzheimer s disease. J Proteome Res. 2011; 10: 2006-2010.
28. Ahmed RM, MacMillan M, Bartley L, et al. Systemic metabolism in frontotemporal dementia. Neurology. 2014; 83: 1812-1818.
29. Czapski GA, Maruszak A, Styczynska M, et al. Association between plasma biomarkers, CDK5 polymorphism and the risk of Alzheimer s disease. Acta Neurobiol Exp (Wars) 2012; 72: 397-411.
30. Dias IH, Polidori MC, Li L, et al. Plasma levels of HDL and carotenoids are lower in dementia patients with vascular comorbidities. J Alzheimers Dis. 2014; 40: 399-408.
31. Doecke JD, Laws SM, Faux NG, et al. Blood-based protein biomarkers for diagnosis of Alzheimer disease. Arch Neurol. 2012; 69: 1318-1325.
32. Ghebranious N, Mukesh B, Giampietro PF, et al A pilot study of gene/gene and gene/environment interactions in Alzheimer disease. Clin Med Res. 2011; 9: 17-25.
33. Gupta VB, Laws SM, Villemagne VL, et al. Plasma apolipoprotein E and Alzheimer disease risk: the AIBL study of aging. Neurology. 2011; 76: 1091-1098.
34. Kandimalla RJ, Wani WY, Anand R, et al. Apolipoprotein E levels in the cerebrospinal fluid of north Indian patients with Alzheimer s disease. Am J Alzheimers Dis Other Demen. 2013; 28: 258-262.
35. Lojkowska W, Witkowski G, Bednarska-Makaruk M, et al. Correlations between cerebellar and brain volumes, cognitive impairments, ApoE levels, and APOE genotypes in patients with AD and MCI. Curr Alzheimer Res. 2013; 10: 964-972.
36. Marksteiner J, Imarhiagbe D, Defrancesco M, et al. Analysis of 27 vascularrelated proteins reveals that NT-proBNP is a potential biomarker for Alzheimer s disease and mild cognitive impairment: a pilot-study. Exp Gerontol. 2014; 50: 114-121.
37. Martinez-Morillo E, Hansson O, Atagi Y, et al. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer s disease patients and controls. Acta Neuropathol. 2014; 127: 633-643.
38. Soares HD, Potter WZ, Pickering E, et al. Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease. Arch Neurol. 2012; 69: 1310-1317.
39. Warren MW, Hynan LS, Weiner MF. Lipids and adipokines as risk factors for Alzheimer s disease. J Alzheimers Dis. 2012; 29: 151-157.
40. Chang L, Wang Y, Ji H, et al. Elevation of peripheral BDNF promoter methylation links to the risk of Alzheimer s disease. PLoS One. 2014; 9: e110773.
41. Schurmann B, Wiese B, Bickel H, et al. Association of the Alzheimer s disease clusterin risk allele with plasma clusterin concentration. J Alzheimers Dis. 2011; 25: 421-424.
42. Xing YY, Yu JT, Cui WZ, et al. Blood clusterin levels, rs9331888 polymorphism, and the risk of Alzheimer s disease. J Alzheimers Dis. 2012; 29: 515-519.
43. Silajdzic E, Minthon L, Bjorkqvist M, Hansson O. No diagnostic value of plasma clusterin in Alzheimer s disease. PLoS One. 2012; 7: e50237.
44. Gupta VB, Wilson AC, Burnham S, et al. Follow-up plasma apolipoprotein E levels in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL) cohort. Alzheimers Res Ther. 2015; 7: 16.
45. Petersen RC, Aisen PS, Beckett LA, et al. Alzheimer s Disease Neuroimaging Initiative (ADNI): clinical characterization. Neurology. 2010; 74: 201-209.
46. Vitali C, Wellington CL, Calabresi L. HDL and cholesterol handling in the brain. Cardiovasc Res. 2014; 103: 405-413.
47. Thambisetty M, Simmons A, Velayudhan L, et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry. 2010; 67: 739-748.
48. Bennett DA, Brayne C, Feigin VL, et al. Development of the standards of reporting of neurological disorders (STROND) checklist: a guideline for the reporting of incidence and prevalence studies in neuroepidemiology. Neurology. 2015; 85: 821-828.
49. Snyder HM, Corriveau RA, Craft S, et al. Vascular contributions to cognitive impairment and dementia including Alzheimer s disease. Alzheimers Dement. 2015; 11: 710-717.
50. Thygesen LC, Ersboll AK. When the entire population is the sample: strengths and limitations in register-based epidemiology. Eur J Epidemiol. 2014; 29: 551-558.
51. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health. 2011; 39 (7 Suppl): 30-33.
52. Soto ME, Secher M, Gillette-Guyonnet S, et al. Weight loss and rapid cognitive decline in community-dwelling patients with Alzheimer s disease. J Alzheimers Dis. 2012; 28: 647-654.
53. Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA. 2007; 298: 786-798.
54. Castelli WP, Doyle JT, Gordon T, et al. HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study. Circulation. 1977; 55: 767-772.
55. Anstey KJ, Christensen H, Butterworth P, et al. Cohort profile: the PATH through life project. Int J Epidemiol. 2012; 41: 951-960.
56. Cadar D, Pikhart H, Mishra G, et al. The role of lifestyle behaviors on 20-year cognitive decline. J Aging Res. 2012; 2012: 304014.